$2.93 billion is the projected 2036 size of the cardiovascular drug discovery market, up from $1.29 billion in 2026, according to a Future Market Insights forecast.
8.6% annual growth is tied to rising cardiovascular disease burdens and sponsor demand for targets backed by human genetics, biomarkers and measurable disease biology.
42.1% of the 2026 approach mix is expected to come from target identification and validation, while heart failure leads therapeutic focus at 36.0%, reflecting persistent treatment gaps.
The UK is forecast to post the fastest country growth at 10.7%, ahead of Germany at 9.2% and South Korea at 8.8%, with genomic cohorts and clinical-study capacity driving momentum.
The outlook still faces high attrition and cost pressures—bringing a new medicine to approval was estimated at $880 million—pushing sponsors to tighten evidence thresholds early.